Welcome to the UMC
the Uppsala Monitoring Centre (the UMC) is the field-name of the WHO Collaborating Centre for International Drug Monitoring. the UMC is responsible for the management of the WHO Programme for International Drug Monitoring.
An independent centre of scientific excellence, the UMC offers a range of products and services, derived from the WHO database reports of Adverse Drug Reactions (ADRs) from healthcare providers and patients in member countries of the WHO Programme. There is no other official body with as independent and global perspective on drug safety as the WHO and its Collaborating Centre, the UMC. We provide essential resources for regulatory agencies, health professionals, researchers, the pharmaceutical industry.
Activities of the UMC include:
- co-ordinating the WHO Programme for International Drug Monitoring
- collecting, assessing and communicating information from member countries about the benefits, harm, effectiveness and risks of drugs
- collaborating with member countries in the development and practice of pharmacovigilance (Click for WHO definition of pharmacovigilance)
- alerting regulatory authorities of member countries about potential drug safety problems via the WHO signal process
|
We welcome contact from those involved or interested in drug safety and public health in academia, government, NGOs and the pharmaceutical industry.
Message from the Director
Click here for the latest message from UMC Director Ralph Edwards